Influenza News and Research

Latest Influenza News and Research

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012

Rep. Sensenbrenner sends second letter inquiring about U.S. government's review of controversial H5N1 studies

"A senior Republican in the U.S. House of Representatives is asking more questions about how the U.S. government reviewed two controversial H5N1 avian influenza studies, and how it wrote a new policy for reviewing taxpayer-funded studies that might be used for good and evil," ScienceInsider reports.

25 Apr 2012

Bats may be a common source of many viral diseases

Where do viruses dangerous to humans come from, and how have they evolved? Scientists working with Prof. Dr. Christian Drosten, Head of the In-stitute for Virology at the Universit-tsklinikum Bonn, have made significant progress in answering this question. "We already knew from prior studies that bats and rodents play a role as carriers of paramyxoviruses," said Prof. Drosten.

25 Apr 2012

Immunosignatures can yield reliable and highly stable diagnostic results

Identifying diseases at an early, presymptomatic stage may offer the best chance for establishing proper treatment and improving patient outcomes. A new technique known as immunosignaturing harnesses the human immune system as an early warning sentry-one acutely sensitive to changes in the body that may be harbingers of illness.

24 Apr 2012

Text messaging increases flu vaccination coverage in low-income children

A text messaging intervention with education-related messages sent to parents increased influenza vaccination coverage compared with usual care in a traditionally hard-to-reach, low-income, urban, minority population of children and adolescents, although coverage overall remained low, according to a study in the April 25 issue of JAMA.

24 Apr 2012

U.S. gives go-ahead on publication of H5N1 research; Dutch regulators continue to debate

The U.S. government on Friday formally accepted a recommendation from the National Science Advisory Board for Biosecurity (NSABB) "to publish two controversial studies of the H5N1 avian influenza virus, moving the pair of papers another step closer to publication," ScienceInsider reports.

24 Apr 2012

BAMC/SAMMC researcher develops microemulsion vaccine carrier

A researcher at the Brooke Army Medical Center (BAMC)/San Antonio Military Medical Center (SAMMC) will present findings this week on a new potential vaccine carrier that he hopes will extend the shelf life of and aid in the stockpiling of critical vaccines.

23 Apr 2012

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.

20 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

White House science adviser responds to inquiry regarding handling of H5N1 research controversy

"White House science adviser John Holdren has replied to questions asked last month by Representative Jim Sensenbrenner (R-Wisc.) about how the Obama Administration has handled the controversy surrounding two studies that showed how to make the H5N1 avian influenza virus transmissible between mammals," ScienceInsider reports.

19 Apr 2012

1 in 5 Australians expect antibiotics for coughs and colds: New NPS campaign

The survey also revealed a plethora of misconceptions when it comes to antibiotics with only half of respondents knowing that bacteria are becoming resistant to antibiotics. Only 40% knew antibiotics should not be taken for viruses and many (40%) did not know that taking antibiotics when they’re not needed contributes to antibiotic resistance. More than half did not know resistance increases when you don’t complete the course as directed and in general, the youth audience had less knowledge.

18 Apr 2012

Large childhood immunization campaign begins in Haiti, with support from U.S., other international partners

Haiti, the U.S. and other international partners on Monday launched "a nationwide vaccination campaign in the Caribbean country that seeks to curb or prevent infectious diseases, health officials said," the Associated Press/Fox News reports.

18 Apr 2012

Imaxio closes EUR 2.9 million funding round

Imaxio, a biopharmaceutical company specialized in the areas of vaccines and genomics, announces today that it has finalized a funding round in which it raised EUR 2.9 million from its principal shareholder, Pradeyrol Developpement.

17 Apr 2012

Flu outbreak at veterans home

State Veterans' Affairs Commissioner Linda Schwartz told The Associated Press that the veterans were taken to Hartford Hospital after a number began complaining of flu-like symptoms. The 18 men live at the Connecticut State Veterans Home in either the Sgt. John L. Levitow Veteran's Health Center or a residential facility.

17 Apr 2012

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

Flu shots offered to populations at risk at the beginning of season

All Care Inala Medical Centre doctor Michael Ho said flu shots were becoming more popular each year. “Flu seasons tends to begin in late March early April to June,” he said. “More and more people are opting to get vaccinations because they are promoted well within the community.” He added, “It is particularly important for elderly people to be immunized because their immune system is already not at its best…This is also the case for people who have chronic medical conditions like diabetes, severe asthma, or heart disease. With their current condition, if they catch the flu they can end up with a worse outcome.”

12 Apr 2012

Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M Integrated Cycler.

From Quest Diagnostics 12 Apr 2012

PURE Bioscience launches new disinfectant/sanitizer product

PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported the launch of the PURE Complete Cleaning, Sanitizing and Disinfecting System.

12 Apr 2012

Influenza vaccine recommended but select the appropriate vaccine

Further to advice issued by the RACGP and the Chief Medical Officer, NPS is encouraging health professionals to offer their patients influenza vaccination, especially for those at risk, but to be aware that the choice of influenza vaccine is important, especially for children.

11 Apr 2012

New method for direct identification of antigens

The immune system is a vital part of our defenses against pathogens, but it can also attack host tissues, resulting in autoimmune disease. The antigens that induce destructive immune reactions can now be identified directly - without any prior knowledge of their possible structure.

11 Apr 2012

Influenza News and Research

Latest Influenza News and Research

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Rep. Sensenbrenner sends second letter inquiring about U.S. government's review of controversial H5N1 studies

Bats may be a common source of many viral diseases

Immunosignatures can yield reliable and highly stable diagnostic results

Text messaging increases flu vaccination coverage in low-income children

U.S. gives go-ahead on publication of H5N1 research; Dutch regulators continue to debate

BAMC/SAMMC researcher develops microemulsion vaccine carrier

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

White House science adviser responds to inquiry regarding handling of H5N1 research controversy

1 in 5 Australians expect antibiotics for coughs and colds: New NPS campaign

Large childhood immunization campaign begins in Haiti, with support from U.S., other international partners

Imaxio closes EUR 2.9 million funding round

Flu outbreak at veterans home

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

Flu shots offered to populations at risk at the beginning of season

Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test

PURE Bioscience launches new disinfectant/sanitizer product

Influenza vaccine recommended but select the appropriate vaccine

New method for direct identification of antigens

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Influenza News and Research

Latest Influenza News and Research

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in